Evaluation of soft-tissue sarcoma therapy response during neoadjuvant radiotherapy through quantification of free circulating tumor DNA (ctDNA) and multiparametric MRI (mpMRI)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00027479

Enrollment

Registered

2021-12-21

Start date

2022-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C49

Interventions

Group 1: neoadjuvant radiotherapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: biopsy confirmed sarcoma, neoadjuvant radiotherapy

Exclusion criteria

Exclusion criteria: terminal kidney failure, symptomatic anemia

Design outcomes

Primary

Measure	Time frame
Detection of biomarkers that correlate with disease activity.	—

Secondary

Measure	Time frame
Comparison of the new biomarkers with imaging.	—

Countries

Germany

Contacts

Public ContactS. U. Eisenhardt

Klinik für Plastische- und HandchirurgieUniversitätsklinikum Freiburg

steffen.eisenhardt@uniklinik-freiburg.de+49 761 270-28170

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026